Page number 7
4 Investor presentation First three months of 2022 Strategic Aspirations 2025 | High Purpose and sustainability (ESG) Progress towards zero environmental impact: • Carbon emissions increased by 46% vs first quarter of 2021 and decreased 25% vs first quarter of 2019 Adding value to society : • Positive scientific opinion from EMA on human insulin with more flexible storage option without refrigeration • Two months’ supply of diabetes and haemophilia medication donated to the Ukrainian Ministry of Health Being recognised as a sustainable employer: • Share of females in senior leadership positions has increased to 37% from 35% in the first quarter of 2021 Diabetes value market share increased by 1.2 percentage point to 30.5% 1 Obesity care sales increased by 107% at CER to DKK 3.4 billion Rare disease sales increased by 3% at CER to DKK 5.4 billion Commercial execution 1 MAT (Moving annual total) value market share. IO: International Operations The strategic aspirations are not a projection of Novo Nordisk's financial outlook or expected growth.
Page number 8
Innovation and therapeutic focus Novo Nordisk ® hlights first three months 2022 Further raise innovation bar for Diabetes treatment: • Approval of Ozempic ® 2.0 mg in the US • Successful completion of first phase 3 trial with once- weekly insulin icodec • Phase 1 trial with Ideal Pump insulin successfully completed • Phase 1 initiated with a once-daily oral GLP-1/GIP agonist Strengthen and progress Rare disease pipeline • Concizumab phase 3 trial successfully completed in people with haemophilia A and B with inhibitors Sales growth of 18% and Operating profit growth of 18%: • Sales in International Operations grew by 13% • Sales in the US grew by 23% with 67% of sales coming from products launched since 2015 Gross margin positively impacted by continued productivity gains in Product Supply Free cash flow of DKK 21.6 billion and DKK 20 billion returned to shareholders during first quarter Financials
